ImmunoCellular Therapeutics (IMUC) Receives 'Going Concern' Opinion from Auditor
Tweet Send to a Friend
ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) today announced that, as previously disclosed in its Annual Report on Form 10-K for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
